Novel Immunotherapy-Based Combinations Prompt Key Treatment Considerations in RCC
November 4th 2022Bradley McGregor, MD, discusses the factors that affect frontline treatment decisions for patients with advanced RCC, the importance of longer-term follow-up of phase 3 trials in kidney cancer, and the benefits of dual immunotherapy and immunotherapy/TKI treatment combinations.
Read More
BRCA Mutations, HRD Status Drive PARP Inhibitor Selection in Ovarian Cancer Maintenance
November 3rd 2022Bobbie J. Rimel, MD, discusses how PARP inhibitors are deployed across different treatment settings of ovarian cancer, the recent market withdrawal of PARP inhibitors in later-line indications, and ongoing research efforts at Cedars-Sinai Medical Center for patients with ovarian cancer.
Read More
Azacitidine-Based Combinations Represent New Treatment Possibilities in MDS
November 2nd 2022Mikkael A. Sekeres, MD, MS, discussed the changes to the classifications of MDS, the evolution of targeted therapies for patients with acute myeloid leukemia, and approaches for patients with bone marrow failure syndromes.
Read More
Treatment Opportunities Expand for HER2+ Breast Cancer With Brain Metastases
October 31st 2022Suchita Pakkala, MD, discussed how treatments like tucatinib and fam-trastuzumab deruxtecan-nxki have widened the armamentarium for patients with brain metastases; the importance of enrolling these patients in clinical trials; and what future treatment sequencing might look like for this population.
Read More
Sunvozertinib Showcases Early Safety, Efficacy in EGFR Exon 20–Mutated NSCLC
October 30th 2022D. Ross Camidge, MD, PhD, discusses the potential utility of sunvozertinib in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations, the efficacy and safety data observed with the agent, and future research directions.
Read More
Genomic Testing and ctDNA Add to Personalized Treatment Approach in Metastatic CRC
October 29th 2022Benjamin Adam Weinberg, MD, discussed the expanding role of circulating tumor DNA in CRC and the various testing methods, the utilization of liquid biopsies, and the need for up-front genetic testing to identify molecular alterations.
Read More
Trastuzumab Deruxtecan Could Challenge Frontline Trastuzumab/Pertuzumab Combo in HER2+ Breast Cancer
October 27th 2022Sara A. Hurvitz, MD, discusses the evolving treatment paradigm in HER2-positive breast cancer, ongoing research in the space, and developments in the treatment of triple-negative breast cancer.
Read More
Exploration of ADCs Highlights the Drive for Personalized Treatment in Ovarian Cancer
October 26th 2022Rodney Rocconi, MD, discusses the continued exploration of antibody-drug conjugates in patients with ovarian cancer, biomarkers and agents under investigation in the space, and the ongoing research being conducted at the O'Neal Comprehensive Cancer Center.
Read More
Cemiplimab Monotherapy Continues to Generate Responses in Locally Advanced or Metastatic CSCC
October 25th 2022Single-agent cemiplimab demonstrated safety and efficacy in patients with locally advanced or metastatic cutaneous squamous cell carcinoma who comprised group 6 of the phase 2 EMPOWER-CSCC-1 trial that was in line with what was previously reported in groups 1, 2, and 3 of the study.
Read More
Real-World Data Could Help Inform Treatment Sequencing Decisions in HR+/HER2- Breast Cancer
October 24th 2022Megan Kruse, MD, discusses the evolving treatment landscape in HR-positive, HER2-negative breast cancer, how the approval of fam-trastuzumab deruxtecan-nxki has affected sequencing choices in HER2-positive disease, and the importance of addressing racial disparities in breast cancer care.
Read More
Stark Differences in Mortality Rates Emphasize Ongoing Racial Disparities in Breast Cancer
October 24th 2022Bridget A. Oppong, MD, discussed the importance of recognizing and addressing gaps in outcomes between patients with breast cancer in different racial groups. She also addressed the need for better advocacy for Black patients and advocated for improved screening guidelines to close the gap in racial disparities in breast cancer care.
Read More
Immunotherapy and BRAF-Targeted Therapy Fill Expanded Roles Across Melanoma
October 21st 2022Immunotherapy and targeted therapy combinations containing BRAF and MEK inhibitors have carved out roles in different settings of melanoma, which has given clinicians different options for treatment sequencing.
Read More
ctDNA Helps Predict Recurrence in Real-World Analysis of Patients With Resected CRC
October 21st 2022Stacey A. Cohen, MD, discusses the results of real-world analysis of patients with resected stage I-III colorectal cancer, how circulating tumor DNA status correlated with recurrence rates, and how these real-world data compared with previous observational studies.
Read More
Immunotherapy-Based Combinations Remain the Focus of Frontline Treatment in Metastatic RCC
October 20th 2022Rana R. McKay, MD, discusses the evolution of frontline treatment options for metastatic RCC, and the key clinical trials that have shifted the treatment paradigms in metastatic castration-resistant prostate cancer, nonmetastatic castration-resistant prostate cancer, and advanced prostate cancer.
Read More
Uproleselan Plus Chemotherapy Could Provide MRD Benefit in Relapsed/Refractory AML
October 17th 2022Although the exact role of minimal residual disease in patients with acute myeloid leukemia requires further definition, MRD status could help provide a clearer pathway for treatment decisions in this patient population.
Read More
Dinutuximab Plus GM-CSF Does Not Improve DCR in Recurrent Osteosarcoma
October 16th 2022R. Lor Randall, MD, FACS, discusses the poor prognosis associated with recurrent pulmonary osteosarcoma, the data from the AOST1421 trial of dinutuxumab plus granulocyte-macrophage colony-stimulating factor, and the need for expanded treatment options in osteosarcoma.
Read More
Evolving Knowledge of BTK Inhibitors Continues to Shape Treatment Landscape in CLL
October 14th 2022Jonathon B. Cohen MD, MS, discusses the management of chronic lymphocytic leukemia with BTK inhibitors, updates in the treatment of acute myeloid leukemia, and how CAR T-cell therapy could improve patient outcomes in diffuse large B-cell lymphoma and mantle cell lymphoma.
Read More
Targeted Therapy Combinations Provide Multiple Treatment Options in BRAF-Mutated Melanoma
October 12th 2022Jeff Yorio, MD, discussed the decision-making process for treating patients with BRAF-mutant melanoma, the use of immunotherapy in melanoma, and the management of cutaneous squamous cell carcinoma and basal cell carcinoma.
Read More
González-Martín discusses the updated long-term efficacy and safety data from the PRIMA study, the importance of utilizing PARP inhibitors in patients with homologous recombination–deficient tumors, and the benefit observed with niraparib in those with homologous recombination–proficient tumors.
Read More
Dostarlimab Elicits Survival Benefit in dMMR/MSI-H Advanced Endometrial Cancer
October 11th 2022Single-agent dostarlimab-gxly produced progression-free survival and overall survival benefits in patients with advanced or recurrent mismatch repair–deficient/microsatellite instability–high endometrial cancer.
Read More
Frontline Avelumab Maintenance Displays Long-Term Benefit in Advanced Urothelial Carcinoma
October 10th 2022Jeanny B. Aragon-Ching, MD, FACP, discusses the results of the subgroup analysis in patients with urothelial carcinoma who received frontline avelumab maintenance for at least 12 months on the phase 3 JAVELIN Bladder 100 trial.
Read More
Gilteritinib Induces Encouraging Responses in Newly Diagnosed FLT3-Mutated AML
October 9th 2022Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.
Read More
Neoadjuvant Radioimmunotherapy Demonstrates Feasibility in Locally Advanced Urothelial Carcinoma
October 7th 2022Sebastian C. Schmid, MD, discusses the results of the RACE IT trial, what the data mean for patients with locally advanced urothelial carcinoma, and the next steps for researching neoadjuvant radioimmunotherapy in this patient population.
Read More
Durvalumab, Tremelimumab, and Chemotherapy Elicit Promising Long-Term OS Rates in NSCLC
October 6th 2022Melissa L. Johnson, MD, expands on the updated data from the POSEIDEN trial, the rationale for investigating the combination, and what these results mean for the treatment of metastatic non–small cell lung cancer.
Read More
Patient-Reported Outcomes Support Use of Trastuzumab Deruxtecan in HR+/HER2-Negative Breast Cancer
October 6th 2022Fam-trastuzumab deruxtecan-nxki preserved quality of life vs physicians choice of treatment in patients with advanced, hormone receptor–positive/HER2-low metastatic breast cancer.
Read More
Loncastuximab Tesirine/Rituximab Elicits Promising Anti-Tumor Activity in Relapsed/Refractory DLBCL
October 3rd 2022Loncastuximab tesirine-lpyl combined with rituximab demonstrated encouraging antitumor activity and a feasible safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More